1. (valid email required)
 

cforms contact form by delicious:days

Archive for May, 2010

CRi Imaging Technology Enables Biomarker Analysis of Cancer Drugs with Skin Biopsies

Clinical Results with Non-Invasive, Quantitative Method Presented at AACR

Woburn, Mass. April 19, 2010 – A research team today reported clinical results of a new method for analyzing the molecular activity of cancer drugs for solid tumors using skin biopsies. The approach, enabled by Cambridge Research & Instrumentation, Inc. (CRi)’s imaging and analysis systems, was presented in a poster session at the American Association of Cancer Research’s (AACR) Annual Meeting in Washington D.C.

“This research underscores the ability of CRi’s optical imaging and analysis systems to provide innovative tools to advance cancer drug development,” said George Abe, President and CEO of CRi. “The study relies on the ability of our multispectral imaging and analysis systems, specifically Nuance and inForm, to discriminate between multiple, co-localized markers in intact tissue.”

Study Details

The study presented was a phase 1b trial to assess whether increased levels of a protein called pCDC2 could serve as a biomarker for molecular target engagement for inhibitors of a cell division cycle-related protein called Wee kinases, especially used in combination with DNA damaging agents. The researchers collected biopsies from 32 patients at three time points before and after infusions of chemotherapy regimens containing gemcitabine, cisplatin or carboplatin.

The researchers used the CRi Nuance FX system to conduct multiplex analyses of phosphorylated CDC2 and total CDC2 protein. The analyses were conducted on cells of the epidermis, hair follicle and hair bulb. All three pre-specified primary analysis parameters detected significant induction of CDC2 phosphorylation in response to chemotherapy over the time course. Of the tissues studied, the epidermis was most consistently evaluable across the skin biopsies and demonstrated strong induction of CDC2 phosphorylation. Increases in pCDC2 were also observed for hair follicles and bulbs, but these tissues were present in fewer biopsies than epidermis, limiting the number of informative specimens.

The study is entitled “A phase 1b study to evaluate induction of pCDC2 in skin biopsies from patients with solid tumors treated with DNA-damaging chemotherapy.” The authors on the study include Amy Sun, Raymond Lamb, Robert Iannone, Gary Herman, Amy Harmon, and Donald Bergstrom, of Merck Research Laboratories, Anna C. Pavlick of the NYU Cancer Institute, and Lisa M. Dauffenbach and Christopher A. Kerfoot of Mosaic Laboratories.

About CRi

Cambridge Research & Instrumentation, Inc. (CRi) develops and markets optical imaging systems to advance biomedical research and molecular-based drug and diagnostic development. CRi’s patented systems enable researchers and clinicians to quantitate multiple disease and drug response markers in intact tissue samples, at a cellular level or in living small animals. CRi’s products integrate a unique multispectral imaging technology with proprietary image analysis algorithms to achieve unparalleled accuracy and sensitivity, rapidly and cost-effectively. CRi’s award-winning systems include Nuance™ for multispectral imaging on brightfield and fluorescence microscopes; inForm™ automated image analysis software; Vectra™ for high-throughput slide imaging and analysis; and Maestro™ for in-vivo optical imaging. Learn more at www.cri-inc.com.

For more information, contact:

Cambridge Research & Instrumentation, Inc. (CRi)

Cathy Boutin, 781-935-9099

Marketing Manager

cboutin@cri-inc.com

Commonwealth Creative Associates

Jamie Bull, 508-620-0791

Digital Media Strategist

jamieb@commcreative.com

Commonwealth Creative Associates

Donna Phelps, 508-620-0791

Senior Account Executive

donnap@commcreative.com

CRi Imaging Technology Enables Biomarker Analysis of Cancer Drugs with Skin Biopsies
A research team today reported clinical results of a new method for analyzing the molecular activity of cancer drugs for solid tumors using skin biopsies. The approach, enabled by Cambridge Research & Instrumentation, Inc. (CRi)’s imaging and analysis systems, was presented in a poster session at the American Association of Cancer Research’s (AACR) Annual Meeting in Washington D.C. »

CRi Customer’s Use of Imaging Systems and Software Featured in The Dark Report

Woburn, Mass. April 8, 2010- A 7-page article in the March 15 issue of the respected medical industry publication The Dark Report describes how Dr. Michael D. Feldman at the Hospital of the University of Pennsylvania uses his Nuance™ and Vectra™ multispectral imaging systems and inForm™ automated image analysis software for advancing the field of pathology.

The article refers to CRi’s systems as smarter than current conventional color imaging systems as they utilize sophisticated multispectral and morphological analysis. Dr. Feldman, a CRi customer and NIH SBIR collaborator, emphasizes how CRi’s systems and software allow the analysis of multiple protein marker antibodies in individual tissue sections without having to resort to serial sections where colocalization studies and tissue registration can be problematic. CRi’s inForm software features automated pattern-recognition and segmentation that presents the pathologist with analysis based on user-input, leveraging and augmenting the experience of the pathologist.

If you would like to receive a free copy of the article from The Dark Report, contact CRi at sales@cri-inc.com or call us at 1-800-383-7924 x158. We will send you a link to download the article as a copy-protected PDF or send you a printed copy.

About CRi

Cambridge Research & Instrumentation, Inc. (CRi) develops and markets optical imaging systems to advance biomedical research and molecular-based drug and diagnostic development. CRi’s patented systems enable researchers and clinicians to quantitate multiple disease and drug response markers in intact tissue samples, at a cellular level or in living small animals. CRi’s products integrate a unique multispectral imaging technology with proprietary image analysis algorithms to achieve unparalleled accuracy and sensitivity, rapidly and cost-effectively. CRi’s award-winning systems include Nuance™ for multispectral imaging on brightfield and fluorescence microscopes; inForm™ automated image analysis software; Vectra™ for high-throughput slide imaging and analysis; and Maestro™ for in-vivo optical imaging. Learn more at www.cri-inc.com.

About the Dark Report

The Dark Report is a periodic intelligence report founded in 1995 by R. Lewis Dark, publisher emeritus. The publication reports news about the latest facts and trends that affect medical laboratories of all kinds. The Dark Group, Inc., and The Dark Report Intelligence Service provide intelligence and strategic market analysis exclusive to CEOs, CFOs, COOs, pathologists, senior laboratory executives, and investment professionals. The Editor-in-Chief is Robert Michel.

Lab leaders rely on THE DARK REPORT for actionable intelligence on important developments in the business of laboratory testing, including compensation trends and notable market milestones.

For more information, contact:

Cambridge Research & Instrumentation, Inc. (CRi)

Cathy Boutin, 781-935-9099

Marketing Manager

cboutin@cri-inc.com

Commonwealth Creative Associates

Jamie Bull, 508-620-0791

Digital Media Strategist

jamieb@commcreative.com

Commonwealth Creative Associates

Donna Phelps, 508-620-0791

Senior Account Executive

donnap@commcreative.com

CRi Customer’s Use of Imaging Systems and Software Featured in The Dark Report
A 7-page article in the March 15 issue of the respected medical industry publication The Dark Report describes how Dr. Michael D. Feldman at the Hospital of the University of Pennsylvania uses his Nuance™ and Vectra™ multispectral imaging systems and inForm™ automated image analysis software for advancing the field of pathology. »

AspenTech aspenONE Global Conference Draws 500 Customers From More Than 200 Process Manufacturing Companies in 43 Countries

BP, Dow Chemical, DuPont, Microsoft, Pfizer, Saudi Aramco, Shell, Technip, and Other Leading Companies to Share Best Practices for Driving Growth in a Changing Global Economy

Burlington, Mass. April 28, 2010 – Aspen Technology, Inc. (NASDAQ: AZPN), a leading provider of software and services to the process industries, today announced that 500 customers from more than 200 process manufacturing companies in 43 countries will convene for the 2010 aspenONE Global Conference being held May 3-6 in Boston. The conference theme – “Capturing Opportunity” – highlights how AspenTech customers from energy, chemicals, engineering & construction, pharmaceuticals, power & utilities, consumer products and other process industries are using aspenONE software to help drive growth in a changing global economy.

Supporting Quote:
Blair Wheeler, Senior Vice President, Marketing, AspenTech
“In a challenging and dynamic economic climate, businesses need to be more agile, improve operational efficiencies, and lower costs in order to capture shifting opportunities. The 2010 aspenONE Global Conference will feature best practice examples from process industry leaders that demonstrate how using advanced software tools improves operations across all facets of process manufacturing. By capturing these opportunities, process industry companies can improve their profitability, drive growth, and outmaneuver the competition. AspenTech is honored to host this conference that brings the best minds in the process industries from over 200 companies from over 40 countries.”

Supporting Resources:

About AspenTech
AspenTech is a leading supplier of software that optimizes process manufacturing – for energy, chemicals, pharmaceuticals, engineering and construction, and other industries that manufacture and produce products from a chemical process. With integrated aspenONE solutions, process manufacturers can implement best practices for optimizing their engineering, manufacturing and supply chain operations. As a result, AspenTech customers are better able to increase capacity, improve margins, reduce costs and become more energy efficient. To see how the world’s leading process manufacturers rely on AspenTech to achieve their operational excellence goals, visit www.aspentech.com.

AspenTech aspenONE Global Conference Draws 500 Customers From More Than 200 Process Manufacturing Companies in 43 Countries
Aspen Technology, Inc. (NASDAQ: AZPN), a leading provider of software and services to the process industries, today announced that 500 customers from more than 200 process manufacturing companies in 43 countries will convene for the 2010 aspenONE Global Conference being held May 3-6 in Boston. »

Latest News

Datawatch Self-Service Data Preparation Platform in High Demand in Healthcare Market

NWN Recognized in CRN Elite 150 For Managed IT Services and Placed on Managed Service Provider 500 List

Bigbelly Unveils Top 2016 Successes for Optimized Collections & Recycling Diversion

Southern California Edison Awards Cadmus MSA to Support Zero Net Energy Schools

» More News


Latest Newsletters

April 2017 – MCRC Announces a New Investment in Baynes Electric Supply

March 2017 – Mass Capital Announces a New Investment in Tri-Wire Engineering Solutions, Inc.

July 2016 – Mass Capital Announces a New Investment in The Cadmus Group, Inc.

» More Newsletters


Archives!